Rahul Ballal, Imara CEO

Imara re­duced to six em­ploy­ees as the biotech, once again pre­clin­i­cal, ex­plores its op­tions

Imara will em­ploy just six peo­ple by the end of this quar­ter as 83% of the staff has been shown the ex­it fol­low­ing the biotech’s Phase IIb flops ear­li­er this month.

The com­pa­ny will like­ly have to find a buy­er or shut down. Imara’s main goal and like­ly on­ly pri­or­i­ty at this point — af­ter end­ing work on its sick­le cell dis­ease and be­ta-tha­lassemia drug — is un­der­go­ing a “com­pre­hen­sive as­sess­ment of its strate­gic op­tions to max­i­mize share­hold­er val­ue.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.